Only a few weeks ago, there was talk of a biotech stock slump, but now some of those same companies are in vogue again, at least in the popular press. Those that make RNA-based therapies are beginning to win over skeptics who are impatiently waiting for commercialization; doubts will remain until they produce a profitable product. Story